A-51 Preliminary Outcome Data of a Clinical Trial Comparing a Neurocognitive Intervention to Supportive Therapy in Individuals with Parkinson's Disease

Lageman, S; Cash, T; Mickens, M
September 2014
Archives of Clinical Neuropsychology;Sep2014, Vol. 29 Issue 6, p522
Academic Journal
Objective: The goal of this study is to evaluate the effects of a neurocognitive rehabilitation intervention compared to a supportive therapy condition in individuals with Parkinson's disease (PD). Method: Individuals with a diagnosis of PD with Mild Cognitive Impairment (MCI) were randomly assigned to receive 8 weeks of a memory and problem solving intervention (n = 8) or supportive therapy (n = 8). Outcomes were assessed at baseline, immediate post, and 6 month follow-up. Results: Significant improvements in learning and memory were noted from baseline to post evaluation, but somewhat contrary to expectation, these changes were found within both conditions, CVLT 1–5 Learning, F(2, 28) = 3.99, p = .030, CVLT Long Delay Free Recall, F(2, 28) = 3.99, p = .030. Participants also evidenced significant improvement in everyday cognitive functioning, F(1, 14) = 4.70, p = .048 and on self-reported stigma associated with PD (PDQ-39 Stigma subscale), F(2, 28) = 5.20, p = .012. Depression symptoms (BDI-II) decreased more for individuals who received the neurocognitive intervention than those who received supportive therapy, particularly from the immediate post evaluation to the 6 month follow up, F(1, 13) = 10.27, p = .007. Conclusion(s): Both neurocognitive and supportive therapy interventions led to improvements on select outcomes. Greater improvement on depression in the neurocognitive intervention may be attributable to the more active problem solving approach taken in this condition compared to supportive therapy. Ongoing data collection will allow for increased statistical power to detect changes; however, initial findings are promising for the use of brief, psychosocial interventions in individuals with PD and MCI.


Related Articles

  • Chronological changes of 123I-MIBG myocardial scintigraphy and clinical features of Parkinson's disease. Koyo Tsujikawa; Yasuhiro Hasegawa; Satoshi Yokoi; Keizo Yasui; Ichiro Nanbu; Tsutomu Yanagi; Akira Takahashi // Journal of Neurology, Neurosurgery & Psychiatry;Sep2015, Vol. 86 Issue 9, p945 

    Objectives: The aim of this study was to investigate chronological changes of 123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy and its relation to clinical features in patients with Parkinson's disease (PD), and to characterise patients with PD with normal or mildly low MIBG uptakes...

  • The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Seifert, Kimberly D.; Wiener, Jonathan I. // American Journal of Neurodegenerative Disease;2013, Vol. 2 Issue 1, p29 

    Background: The diagnosis of Parkinson's disease remains a challenge in patients who have abnormal symptoms or show a lack of response to medication. The imaging technique, DaTscan, can be used to visualize dopamine degeneration in the nigro-striatum, which is associated with Parkinsonian...

  • Parkinson's disease. Worth, Paul // Pulse;Oct2013, p60 

    The article offers tips for diagnosis and management of Parkinson's disease. The author suggests to become aware on unusual symptoms on motor activities. He mentions that symptoms should be clear before treatment to prevent false diagnosis. He states that patients diagnosed with Parkinson's...

  • Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease. Kaasinen, Valtteri; Kinos, Maija; Joutsa, Juho; Seppänen, Marko; Noponen, Tommi // European Journal of Nuclear Medicine & Molecular Imaging;Oct2014, Vol. 41 Issue 10, p1931 

    Purpose: Parkinson's disease (PD) can manifest with a tremor-dominant or a non-tremor (akinetic-rigid) phenotype. Although the tremor-dominant subtype may show a better prognosis, there is limited information on the phenotypic differences regarding the level of striatal dopamine transmission....

  • Transcranial sonography and the pocket smell test in the differential diagnosis between parkinson's disease and essential tremor. Štenc Bradvica, Ivanka; Mihaljević, Ivan; Butković-Soldo, Silva; Kadojić, Dragutin; Titlić, Marina; Bradvica, Mario; Kralik, Kristina // Neurological Sciences;Aug2015, Vol. 36 Issue 8, p1403 

    The aim of this study was to determine the specificity and sensitivity of transcranial sonography (TCS) and the Pocket Smell Test (PST) in differing Parkinson's disease from essential tremor. The results were compared with the dopamin transporter scan (DaTSCAN) findings. Based on the DaTSCAN...

  • An update on the diagnosis and treatment of Parkinson disease. Rizek, Philippe; Kumar, Niraj; Jog, Mandar S. // CMAJ: Canadian Medical Association Journal;11/1/2016, Vol. 188 Issue 16, p1157 

    The article provides information on the update on the diagnosis, management and treatment of the neurodegenerative disorder, Parkinson disease. It discusses the pathophysiology of Parkinson disease, people at risk of the disease, and its diagnosis. Also discussed are the differences between the...

  • Visual Attention and Saccadic Oculomotor Control in Parkinson's Disease. Buhmann, Carsten; Kraft, Stefanie; Hinkelmann, Kim; Krause, Sven; Gerloff, Christian; Zangemeister, Wolfgang H. // European Neurology;Jun2015, Vol. 73 Issue 5/6, p283 

    Background: In patients with Parkinson's disease (PD) we aimed at differentiating the relation between selective visual attention, deficits of programming and dynamics of saccadic eye movements while searching for a target and hand-reaction time as well as hand-movement time. Visual attention is...

  • Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs. Michel, Anne; Downey, Patrick; Van Damme, Xavier; De Wolf, Catherine; Schwarting, Rainer; Scheller, Dieter // PLoS ONE;8/31/2015, Vol. 10 Issue 9, p1 

    In Parkinson’s disease (PD), dopaminergic therapies are often associated with the development of motor complications. Attention has therefore been focused on the use of non-dopaminergic drugs. This study developed a new behavioural method capable of demonstrating the added value of...

  • Parkinson’s disease. Roller, Louis; Gowan, Jenny // Australian Journal of Pharmacy;Dec2016, Vol. 97, p48 

    The article reports on the view of author that pharmacist have generally focused on giving medications for Parkinson's disease, but should also give importance to counselling patients and their carers. lack of awareness in the health and social stigma have contributed to slow medical care being...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics